Download PDF
Dtsch Med Wochenschr 2005; 130(38): 2149-2154
DOI: 10.1055/s-2005-916357
Übersichten
Hämatologie/Onkologie
© Georg Thieme Verlag Stuttgart · New York

Aktuelle Therapie des follikulären Lymphoms

Treatment of follicular lymphomasM. Dreyling1 , C. Buske1 , W. Hiddemann1
  • 1Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität München, Großhadern
Further Information

Publication History

eingereicht: 15.6.2005

akzeptiert: 25.8.2005

Publication Date:
20 September 2005 (online)

Also available at
    Permissions and Reprints

Glossar

ASCT = autologe Stammzelltransplantation

BMR = Bendamustin/Mitoxantron/Riduximab

CHOP = Cyclophosphamid/Adriamycin/Vincristin/Prednison

CHVP = Cyclophosphamid, Adriamycin, Etoposid, Prednison

CR = komplette Remission

uCR = unconfirmed CR

Dexa-BEAM = Dexamethason, BCNU, Etopsid, Cytosin, Arabinoid, Melphalan

FCM = Fludarabin, Cyclophosphamid, Mitoxantron

FLIPI = Follicular Lymphoma International Prognostic Index

GELA = Groupe D’Etudes des Lymphomes de l’Adulte

GLSG = Deutsche Lymphom Studiengruppe

GOELAMS = Groupe Ouest des Leucemies Aigues Myeloblastiques

GvHR = Graft versus Host Disease

IFN = Interferon

IPI = Internationaler Prognostischer Index

MCP = Mitoxantron/Chlorambucil/Prednison

PBSCT = ASCT

R = Rituximab

SAKK = Schweizer Arbeitsgemeinschaft für Klinische Krebsforschung

TPI = Total Body Irradiation

VCAP = Vincristin, Cyclophosphamid, Adriamycin, Prednison

Literatur

  • 1 Ardeshna K M, Smith P, Norton A. et al . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.  Lancet. 2003;  362 516-522
    Google Scholar
  • 2 Bosch F, Perales M, Cobo F. et al . Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma (abstract).  Blood. 1997;  90 (Suppl 1) 2360
    Google Scholar
  • 3 Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy.  Blood. 2004;  104 2635-2642
    Google Scholar
  • 4 Cheson B D. Radioimmunotherapy of non-Hodgkin lymphomas.  Blood. 2003;  101 391-398
    Google Scholar
  • 5 Cohen Y, Solal-Celigny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.  Haematologica. 2003;  88 811-823
    Google Scholar
  • 6 Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P. et al . Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.  Blood. 2001;  97 101-106
    Google Scholar
  • 7 Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.  J Clin Oncol. 2004;  22 4711-4716
    Google Scholar
  • 8 Deconinck E, Foussard C, Milpied N. et al . High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS.  Blood. 2005;  105 3817-3823
    Google Scholar
  • 9 Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck H P, Wandt H, Unterhalt M, Hiddemann W. The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) significantly increases the Response Rate and prolongs Survival as compared to FCM alone in Patients with Relapsed and Refractory Follicular and Mantle Cell Lymphomas - Results of a Prospective Randomized Study of the German Low Grade Lymphoma Study Group (GLSG).  Blood. 2004;  104 3064-3071
    Google Scholar
  • 10 Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.  Clin Lymphoma. 2004;  5 98-101
    Google Scholar
  • 11 Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J. et al . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.  Blood. 2004;  103 4416-4423
    Google Scholar
  • 12 Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network.  J Clin Oncol. 2005;  23 1088-1095
    Google Scholar
  • 13 Herold M, Pasold R, Srock S. et al . Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).  Blood. 2004;  104 (Suppl 1) 584a
    Google Scholar
  • 14 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis H -E, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M. Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).  Blood. 2005;  (in press)
    Google Scholar
  • 15 Horning S J. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas.  Semin Oncol. 1993;  20 (Suppl 5) 75-88
    Google Scholar
  • 16 Jaffe E S, Harris N L, Stein H, Vardiman J. World Health Organisation Classification of Tumours: Tumours of the Haemopoitic and Lymphoid Tissues. IARC Press, Lyon 2001
    Google Scholar
  • 17 Khouri I F, Saliba R M, Giralt S A. et al . Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.  Blood. 2001;  98 3595-3599
    Google Scholar
  • 18 Klasa R J, Meyer R M, Shustik C. et al . Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine and prednisone in patients with recurrent low-grade non-Hodgkin`s lymphoma previously treated with an alkylating agent or alkylatr-containing regimen.  J Clin Oncol. 2002;  20 4649-4654
    Google Scholar
  • 19 Korsmeyer S J. BCL-2 gene family and the regulation of programmed cell death.  Cancer Res. 1999;  (Suppl) 1693s-1700s
    Google Scholar
  • 20 Lenz G, Dreyling M, Schiegnitz E. et al . Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.  Blood. 2004;  104 2667-2674
    Google Scholar
  • 21 Lenz G, Dreyling M, Schiegnitz E. et al . Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.  J Clin Oncol. 2004;  22 4926-4933
    Google Scholar
  • 22 Marcus R, Imrie K, Belch A. et al . CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.  Blood. 2005;  105 1417-1423
    Google Scholar
  • 23 McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S. et al . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.  J Clin Oncol. 1998;  16 2825-2833
    Google Scholar
  • 24 Nickenig C, Dreyling M, Schiegnitz E. et al . CHOP Inproves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL) - Results of a Randomized Trail of the German Low Grade Lymphoma Study Group (GLSG). Annual Meeting of the American Society of Hematology, San Diego (Abstract).  Blood. 2004;  104 (Suppl 1) 611
    Google Scholar
  • 25 O’Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz A D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma.  J Clin Oncol. 2005;  23 676-684
    Google Scholar
  • 26 Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, Kalla J, Rosenwald A, Muller J G, Ott M M, Muller-Hermelink H K. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3.  Blood. 2002;  99 3806-3812
    Google Scholar
  • 27 Ramanarayanan J, Hernandez-Ilizaliturri F J, Czuczman M. In vivo downregulation of bcl-2 by G3139 (G) enhances Rituximab anti-tumor activity: effect of sequential versus concurrent G3139 administration on survival in a lymphoma-bearing SCID mouse model.  Blood. 2004;  104 (Suppl 1) 392a
    Google Scholar
  • 28 Rohatiner A, Davies A, Apostolidis J, Neuberg D, Matthews J, Nadler L, ALister A, Freedmann A. High dose therapy (HDT) with autologous haematopoietic progenitor cell support as consolidation of remission in patients with follicular lymphoma (FL): Long follow-up of St. Bartholomew’s Hospital (SBH) and Dana-Farber Cancer Institute (DFCI) data.  Ann Oncol. 2005;  16 v48 (Suppl 5)
    Google Scholar
  • 29 Saleh M, Dakhil S, deVos S, Patel-Donnelly. et al . Phase 2 study of Bortezomib and rituximab in patients with indolent non-Hdogkin’s lymphoma (NHL).  Ann Oncol. 2005;  16 v136 (Suppl 5)
    Google Scholar
  • 30 Salles G, Foussard C, Nicolas M. et al . Rituximab Added to aIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients.  Blood. 2004;  104 (Suppl 1) 160a
    Google Scholar
  • 31 Schouten H C, Qian W, Kvaloy S. et al . High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial.  J Clin Oncol. 2003;  1 918-927
    Google Scholar
  • 32 Sebban C, Belanger C, Brousse N. et al . Comparison of CHVP + Interferon with CHOP Followed by Autologous Stem Cell Transplantation with a TBI Conditioning Regimen in Untreated Patients with High Tumor Burden Follicular Lymphoma: Results of the Randomized GELF94 Trial (GELA Study Group).  Blood. 2003;  102 (Suppl 1) 54a
    Google Scholar
  • 33 Solal-Celigny P, Roy P, Colombat P. et al . Follicular Lymphoma International Prognostic Index.  Blood. 2004;  104 1258-1265
    Google Scholar
  • 34 Van Besien K, Loberiza F R, Bajorunaite R. et al . Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.  Blood. 2003;  102 3521-3599
    Google Scholar
  • 35 Weng W K, Czerwinski D, Timmerman J. et al . Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.  J Clin Oncol. 2004;  22 4717-4724
    Google Scholar
  • 36 Winter J N. Controversies in the treatment of follicular lymphomas (grades 1 and 2). In: Heamatology 2004_ASH Educational Book 2004: 208-211
    Google Scholar
  • 37 Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C. et al . Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.  J Clin Oncol. 2002;  20 2453-2463
    Google Scholar

Priv.-Doz. Dr. M. Dreyling

Klinikum Großhadern der Universität München, Medizinische Klinik III

Marchioninistr. 15

81377 München

Phone: 089/70952202

Fax: 089/70952201

Email: Martin.Dreyling@med.uni-muenchen.de

      >